Five weeks after its declaration, the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo remains far from under control. Response efforts have undeniably ramped up, but they still struggle to outpace a virus that continues to advance, cross borders and take lives.

Scaling up is not enough

The commitment on the ground is real. Patient care capacity has surged from fewer than 10 beds to over 500 across 19 health centres in affected zones. Testing has followed a similar trajectory: from 30 tests per day at the start of the outbreak, the DRC can now conduct more than 2,000 daily across nine laboratories covering three provinces. Over 100 recoveries have also been recorded, a reminder that early treatment can make the difference between life and death.

Yet the overall toll remains heavy: 1,094 confirmed cases and 277 deaths to date. Tedros Adhanom Ghebreyesus notes that the epidemic is still outpacing the response. Contact tracing is insufficient, isolation capacity falls short of what is needed, and safe burials remain a daily struggle in communities that are often distrustful or hard to reach.

A virus that ignores borders

The outbreak has now spilled far beyond the DRC provinces of Ituri, North Kivu and South Kivu. Neighbouring Uganda reports 20 confirmed cases and two deaths, all linked to the Congolese strain. More worrying still, France this week confirmed its first case on European soil: a humanitarian doctor from the NGO ALIMA, who returned from a mission in the DRC, tested positive for the Bundibugyo Ebola virus. Now receiving care in a specialised facility, his condition is stable. An epidemiological investigation is under way to identify and monitor his contacts.

This case is a stark reminder of the price paid by health workers on the front line. Nearly 80 healthcare personnel have been infected since the crisis began, prompting renewed calls from the WHO for states to guarantee safe deployment conditions for their humanitarian staff, including the possibility of swift medical evacuation in the event of contamination.

Response hampered, funding shortfall

Beyond the health challenges, the response faces structural hurdles that complicate every intervention. Border closures hinder the movement of teams and equipment. Security incidents multiply in a region scarred by decades of armed conflict. And funding has been slow to materialise, even as the WHO and Africa CDC have launched a continental plan costing 518 million dollars.

There is a glimmer of hope, however: a clinical trial evaluating two antivirals—MBP134 and remdesivir—is set to begin next week in the DRC. Led by a consortium including the DRC National Institute for Biomedical Research, ALIMA, the University of Oxford and the WHO, with support from the United States and Gilead Sciences, this trial could mark a turning point in the fight against an outbreak that, five weeks after its start, is far from contained.

By Mariama Hamani — Analyst